Anika Therapeutics (ANIK) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.45 +0.21%
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 4.83M
Today's EPS Names:
FUSE, INM, TRI, More
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 4.83M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.54, $0.01 better than the analyst estimate of $0.53. Revenue for the quarter came in at $28.7 million versus the consensus estimate of $27.84 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Comscore (SCOR) Misses Q3 EPS by 446c
- Innospec (IOSP) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
